Episode Details
Back to Episodes
Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data
Published 1 month, 2 weeks ago
Description
Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.